Skip to main content

AVCO

Stock

Performance overview

AVCO Price
Price Chart

Forward-looking statistics

Beta
1.08
Risk
100.00%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Company info

Sector
Industry
Website
Employees
Market cap

Fundamentals

Enterprise value$268.4M
Revenue$1.4M
Revenue per employee
Profit margin29.80%
Debt to equity-0.08

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)-$1.10
Dividend per share
Revenue per share$0.16
Avg trading volume (30 day)$291K
Avg trading volume (10 day)$163K
Put-call ratio

Macro factor sensitivity

Growth
Credit
Liquidity
Inflation
Commodities
Interest Rates

Valuation

Dividend yield0.00%
PEG Ratio0.08
Price to sales191.16
P/E Ratio
Enterprise Value to Revenue192.95
Price to book3.17

Upcoming events

Next earnings dayMarch 30, 2022
Next dividend day
Ex. dividend day

News

Avalon GloboCare Adds CAR-NK Cell Therapies To Expand Cellular Immuno-Oncology Platform

Avalon GloboCare Corp (NASDAQ: AVCO) is expanding its cellular immuno-oncology program with the addition of novel Chimeric Antigen Receptor – Natural Killer (CAR-NK) cell therapies. Avalon is leveraging its mRNA-based FLASH-CAR platform to develop autologous and universal CAR-NK technology and cellular therapies for the potential treatment of hematologic malignancies and solid tumors.

Benzinga (February 14, 2022)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free